Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.

Suppr

超能文献

作者信息

Schlaifer D, Attal M, Huguet F, Canal P, Laurent G, Pris J

机构信息

Service d'Hematologie, Purpan Hospital, Toulouse, France.

出版信息

Semin Hematol. 1994 Apr;31(2 Suppl 3):31.

PMID:8073306

Abstract

摘要

相似文献

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.

Semin Hematol. 1994 Apr;31(2 Suppl 3):31.

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.

J Clin Oncol. 1994 Jan;12(1):141-8. doi: 10.1200/JCO.1994.12.1.141.

Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):208-18. doi: 10.1016/j.ijrobp.2003.07.004.

Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.

Cancer. 2005 Mar 1;103(5):970-7. doi: 10.1002/cncr.20891.

Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.

Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.

Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11. doi: 10.1016/j.bbmt.2006.02.009.

Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.

Bone Marrow Transplant. 1999 Sep;24(5):473-81. doi: 10.1038/sj.bmt.1701941.

The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients).

Bone Marrow Transplant. 1991;7 Suppl 2:142.

High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.

Biol Blood Marrow Transplant. 1997 Jun;3(2):98-106.

A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.

Exp Hematol. 1995 Dec;23(14):1581-8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验